NCT02096666 - A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 15, 2014

Primary Completion Date

November 5, 2015

Study Completion Date

December 7, 2018

Conditions

Stomach Neoplasms

Interventions

DRUG

AMG 337

Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)

Trial Locations (4)

277-8577

Research Site, Kashiwa-shi

060-8648

Research Site, Sapporo

216-8511

Research Site, Kawasaki-shi

411-8777

Research Site, Suntou-gun